Structure Therapeutics: GSBR-1290 [60] [61] [60] [61] An oral GLP1R agonist, currently being studied in a double-blinded, placebo-controlled Phase 2a clinical trial
These drugs were originally developed to treat type 2 diabetes, and worked by mimicking the natural hormones that lower blood sugar levels and slow down digestion
These are not finished-product trials of WonderBiotics, were not conducted in GLP-1 medication users, and are not specific to GLP-1 companion use
Underwood previously served as beauty and wellness director at Oprah Daily and O, The Oprah Magazine
Case Study 2: Managing Co-Occurring Medical and ED Needs Client Profile: A 25-year-old female presenting with OSFED, Major Depressive Disorder, and Generalized Anxiety Disorder, admitted to PHP to manage mood, anxiety, and ED symptoms